Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors

Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinico...

Full description

Saved in:
Bibliographic Details
Published in:Journal of digestive diseases 2022-08, Vol.23 (8-9), p.493-499
Main Authors: Dogan, Izzet, Tastekin, Didem, Karabulut, Senem, Sakar, Burak
Format: Article
Language:English
Subjects:
Age
capecitabine
Disease control
Medical prognosis
Metastases
Metastasis
Multivariate analysis
Neuroendocrine tumors
Octreotide
Patients
prognosis
Somatostatin
Statistical analysis
Survival
temozolamide
Temozolomide
Thrombocytopenia
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or lanreotide). Methods Clinicopathological characteristics and treatment outcomes of 43 patients with mGI‐NET were retrospectively evaluated. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier curve. Cox‐regression analysis was used to assess prognostic variables. Results There were 23 (53.5%) men and 20 women (46.5%) with a median age of 59 years (range 27–85 y). Patients were given octreotide (86.0%) or lanreotide (14.0%) with CAPTEM. In patients with well‐differentiated mGI‐NET, median PFS was 17.4 months, and the disease control rate was 71.1%. Patients with poorly differentiated mGI‐NET showed no response, and the median PFS was 4.5 months. Four (9.3%) discontinued the medication due to toxicity. Anemia (37.2%), thrombocytopenia (25.6%), and fatigue (16.3%) were the most prevalent adverse events. The 5‐year OS rate was 61.0% in all patients during a median follow‐up of 33.8 months. In multivariate analysis, age (P = 0.014) and tumor differentiation (P 
ISSN:1751-2972
1751-2980
DOI:10.1111/1751-2980.13123